Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

First-in-human comparison of LY-2775240 and apremilast in healthy volunteers

Nov. 11, 2019

Phase IIb ATLAS study of etokimab fails to meet the primary endpoint

Nov. 11, 2019

Hoth Therapeutics initiates confirmatory study of the AEA-loaded-Z pods in models of lupus

Nov. 7, 2019

Further interim data presented from phase Ib study of EDP-1815 in patients with psoriasis

Nov. 6, 2019

Clinical development of MOR-106 for atopic dermatitis ended for futility

Oct. 29, 2019

BioCryst Pharmaceuticals discloses complement factor D inhibitors

Oct. 29, 2019

Microbion announces phase Ib data for pravibismane in infected diabetic foot ulcers

Oct. 29, 2019

First subject dosed in phase II ADVISE study of etrasimod in atopic dermatitis

Oct. 29, 2019

Arcutis plans phase III program with ARQ-151 for plaque psoriasis

Oct. 28, 2019

Rapt Therapeutics studies oral CCR4 antagonist RPT-193 in first-in-human trial

Oct. 24, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 13, 2026.
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
First cruise ship hantavirus genome points to zoonotic spillover
BioWorld
The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...